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| INTRODUC TI ON
The Sprouty/Spred family functions as crucial negative regulators of Ras/Raf/ERK signaling and is evolutionarily conserved from Drosophila to mammals. [1] [2] [3] [4] Drosophila sprouty was discovered as an antagonist of FGF signaling in 1998. 1, 2 In mammals, there are four Sprouty homologs (Sprouty1-4). Later, Sproutys were shown to suppress ERK activation induced by various growth factors, such as FGF, platelet-derived growth factor, VEGF-A, nerve growth factor, and GDNF in a cell type-and growth factor-specific manner. To suppress the Ras/Raf/ERK pathway, Sprouty proteins contain several conserved amino acid sequences, such as the c-Cbl-binding domain at the N-terminus, which includes a conserved tyrosine residue, the serine-rich motif, and the CRD at the C-terminus.
In 2001, Spred1 and Spred2 were first described as Sproutyrelated proteins by Yoshimura's group, who revealed that both Spred1 and Spred2 function as negative regulators of the Ras/Raf/ ERK pathway through binding to Ras and suppression of Raf activation. 3, 4 These Spred proteins have 3 domains of EVH-1 in the N-terminus, KBD, and Sprouty-related CRD in the C-terminus.
Spred3, which lacks a functional KBD, was also cloned by the same group. Spreds are expressed in various organs such as lung, heart, kidney, brain, testis, thymus, uterus, and ovary, but the expression pattern differs among Spreds. Germline loss-of-function mutations in Spred1 causes Legius syndrome, which shows a similar phenotype to NF1 with café-au-lait spots and axillary freckling, but without cutaneous neurofibromas, or any detectable NF1 mutation. 5 After this report, it was shown that Spred1 binds to neurofibromin (encoded by NF1) by its EVH-1 domain and recruits neurofibromin to the plasma membrane, which explains the overlapping features of the two human diseases. 6 Spreds are also known to regulate inflammatory signaling in various organs. Spred1 negatively modulates airway eosinophilia and hyperresponsiveness without affecting T-cell differentiation and inhibits interleukin-5-induced ERK activation. 4 Spred2 deficiency increases the severity of lipopolysaccharideinduced acute lung inflammation 7 and liver injury 8 in mice, whereas Spred2 −/− mice showed resistance to DSS-induced acute colitis. 9 The Ras/Raf/ERK pathway is dysregulated by many factors in most cancers. There are numerous negative regulators for finetuning of the Ras/Raf/ERK pathway, including Ras GTPase-activating proteins, MAPK phosphatases, and the Sprouty/Spred family. 2 As the Sprouty/Spred family is one of the most important suppressors in the Ras/Raf/ERK pathway, many researchers have intensively investigated the roles of Sproutys and Spreds as tumor suppressors during tumorigenesis and metastasis. In this review, we discuss the elucidated roles of the Sprouty/Spred family in cancer. Spreds inhibit ERK activation by associating with Ras and neurofibromin and suppressing the phosphorylation and activation of Raf. 3, 6 Spreds can also modulate the activation of the small GTPases, Ras, Rap1, and Rho. 3 In Spred1, the inhibition of the Ras/Raf/ERK pathway was recognized when its 2 tyrosine (Y) residues 377/420 were phosphorylated. 11 Three other tyrosine residues (Y303/343/353) within the CRD are necessary for regulating Spred2 activity. 12 Spred1 −/− mice have a shortened face, melanin deposits in the spleen, and enhanced functions of hematopoietic stem cells.
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Overexpression of Spred2 reduced the number of hematopoietic stem cells in the aorta-gonad-mesonephros culture, and hematopoietic stem cells from Spred2 −/− mice were upregulated. 4 We gener- 
TA B L E 1 (Continued)
The Sprouty/Spred family negatively regulates VEGF-A and VEGF-C signaling pathways as well as angiogenesis and lymphangiogenesis, both of which are important processes for tumor development. 4 These findings suggest that expression of the Sprouty/Spred family in the tumor microenvironment also indirectly affects tumorigenesis and metastasis. Actually, we showed that s.c. tumors in Sprouty4 −/− mice grow much faster than those in WT mice through enhanced neovascularization. 29 It has recently been reported that the loss of Sprouty1 and Sprouty2 promotes the survival of effector CD8 + T cells, resulting in the formation of more protective memory CD8+ T cells. 30 Another study has shown that Spred1 is upregulated in CD8 + tumorinfiltrating lymphocytes in a TGF-β-dependent manner. 31 These findings implicate the Sprouty/Spred family as the new potential targets in cancer immunotherapy.
| ROLE S OF S PROUT Y/S PRED DURING TUMORIG ENE S IS AND ME TA S TA S IS
Aberrant activation of the Ras/Raf/ERK pathway induces excessive cell proliferation and tumorigenic behavior. 
| Sprouty/Spred and HCC
It is thought that deregulation of the Ras/Raf/ERK pathway in HCC is due to downregulation of the negative regulators, including Sproutys, Spreds, and dual-specificity phosphatases. In HCC, the expression of Sprouty1 is increased, whereas the expression of Sprouty2 and Sprouty4 is decreased, compared with the levels in corresponding nontumor tissues. [32] [33] [34] Sprouty2 is suggested to be a candidate tumor suppressor in HCC and is an independent factor associated with postoperative recurrence in HCC. 34 Sprouty2-Y55F, a dominant negative mutant form of Sprouty2, promotes Akt-induced HCC development through the activation of ERK1/2 and pyruvate kinase M2
and cooperates with activated β-catenin to induce HCC in mice. 2 In human HCC tissues, the expression of Spred1 and Spred2 was found to be lower than that of adjacent nontumoral tissue and the expression levels of Spred1 and Spred2 were negatively correlated with the rates of tumor invasion and metastasis. 54 Spred1 overexpression in human HCC cell lines inhibited increased cell proliferation and negatively regulated the secretion of MMP-2/9. 54 Another group reported that, in a human HCC cell line, Spred2 overexpression inhibited cell proliferation and migration and induced apoptosis and Spred2 knockdown promoted tumor growth in vivo. 61 Silibinin, a natural polyphenolic flavonoid, plays an antitumorigenic role in HCC through inhibition of the ERK1/2 cascade through the upregulation of Spreds. 62 Taking these findings together, the Sprouty/Spred family inhibits the proliferation and migration of human HCC.
TA B L E 2 Expression of Spreds in various human cancer types
| Sprouty and pancreatic cancer
Only a few papers have been published about the role of Sproutys and Spreds in pancreatic cancer. Dual-specificity tyrosine phosphorylation-regulated kinase 1A, which is highly expressed in pancreatic ductal adenocarcinoma, stabilizes c-Met through Sprouty2 phosphorylation, thereby resulting in the promotion of tumor growth. 63 In pancreatic cancer cells, miR-21 targets Sprouty2
for promoting EGF-induced cell proliferation. 64 Sprouty4 does not affect β-cell carcinogenesis in mice, although it regulates endocrine pancreas development. 
| Sprouty/Spred and CRC
The role of Sproutys, especially Sprouty2, in CRC is still controversial. The expression of Sprouty2 is reported to be reduced in human CRC and is inversely correlated with the expression of miR-21. 37 The expression level of Sprouty4 is also reduced in human CRC due to DNA methylation and serves as an independent predictor of overall survival. 36 The expression of Sprouty2, which promotes the cytotoxic effect of 5-fluorouracil and metformin, is downregulated by miR-21 in a human colon cancer cell line. 65 Sprouty2 also increases the sensitivity to gefitinib, an EGFR inhibitor, by increasing the expression of phosphorylated and total EGFR in human CRC cell lines. 2 Moreover, in colon cancer cells, Sprouty2 induces PTEN expression and suppresses the PI3K-Akt pathway in addition to the Ras/Raf/ ERK pathway. 37 However, in contrast, Holgren's group reported that Sprouty2 is upregulated in human CRC samples and functions as an oncogene by inducing the expression of c-Met. 38 The same group showed that the downregulation of Sprouty2 induces E-cadherin and p21 expression and inhibits EMT and cell proliferation. 39 Sprouty2 also increases ZEB1 expression through Akt and Src activation and induces EMT in colon cancer cells.
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A study about Spreds and CRC was carried out using an azoxymethane/DSS-induced colon tumor model. 9 The number and size of colon tumors in Spred2 −/− mice were lower and smaller than those in WT mice. 9 Knockdown of Spred2 in a human colon cancer cell line modestly increased the cell proliferation and migration. 9 To elucidate the role of Spreds in CRC, further investigation is necessary.
| Sprouty/Spred and upper digestive tract cancer
In gastric cancer, low expression of Sprouty2 is associated with poor prognosis via the upregulation of FGFR2-induced ERK activation, positive lymphatic invasion, and metastasis. 40 MicroRNA-23a, which is considered as an oncogene, is upregulated in gastric cancer samples and promotes cell proliferation and metastasis by targeting Sprouty2. 67 MicroRNA-592 also enhances the proliferation and invasion of gastric cancer cells by targeting Sprouty2. 41 In esophageal squamous cell carcinoma, lncRNA CCAT1 is upregulated and induces the histone methylation of the promoter of Sprouty4, resulting in the suppression of Sprouty4 expression. 68 MicroRNA-182 was found to be upregulated in malignant oral carcinoma tissues and overexpression of miR-182 sustained Ras/Raf/ERK signaling activation and promoted cell proliferation through the inhibition of Spred1, whereas the knockdown of miR-182 revealed the inverse effect using a human tongue squamous cell carcinoma cell line. 56 The expression of Spred1 in esophageal cancer including both squamous cell carcinoma and adenocarcinoma was analyzed. 57 Spred1 was downregulated compared with that in nonmalignant tissue in two-thirds of esophageal cancer
patients. An inverse correlation of Spred1 and miR-144, whose upregulation was seen in dysplastic esophageal cancer cells, was also observed. 57 
| Sprouty/Spred and melanoma
Sprouty2 directly binds to and suppresses WT BRAF and is downregulated in WT BRAF melanoma cells. 2 However, it does not bind to or inhibit BRAF V600E and is instead upregulated in BRAF-mutant melanoma cells. 2 Sprouty2 is also related to the induction of resistance to BRAF inhibitor in BRAF-mutant melanoma cells. 69 Salmonella typhimurium strain VNP20009 harboring Sprouty2-expressing plasmid suppresses the s.c. growth of B16F10, a murine melanoma cell line, in vivo. 70 The knockdown of Spred1 and Spred2 shows an effect similar to that of an MEK inhibitor and protects against apoptosis of BRAF V600E-positive melanoma cell lines. 71 The inhibition of the ERK pathway can even worsen the tumorigenesis of melanoma under certain conditions. Recently, biallelic inactivation mutations of Spred1 have been reported in patients with mucosal melanoma. 
| Sprouty/Spred and prostate cancer
The expression of Sprouty1 and Sprouty2 is reduced in human prostate cancer, and Sprouty2 expression is mainly suppressed by epigenetic inactivation. 2, 42, 43 Sprouty4 expression is also reduced by methylation of the Sprouty4 promoter region in human prostate cancer. 44 Only loss of Sprouty2 induces growth arrest and suppresses prostate tumorigenesis through PP2A-mediated nuclear accumulation of PTEN. 73 However, the loss of Sprouty2, followed by the inactivation of PP2A or PTEN, accelerates prostate tumor progression. 73 Concomitant suppression of Sprouty isoforms and Spred isoforms has been reported in prostate cancer, suggesting a dose effect of negative regulators. 43, 74 Loss of both Sprouty1 and Sprouty2 in prostate epithelium results in ductal hyperplasia and low-grade prostatic intraepithelial neoplasia in mice.
The expression of Spred2, but not Spred1, was elucidated to be downregulated in human prostate cancer. 58, 74 Spred2 overexpression in a human prostate cancer cell line reduced ERK activation and decreased cell proliferation and migration, and Spred2 knockdown indicated the inverse effect. 58 Thus, Spred2 rather than Spred1 appears to be involved in prostate cancer as a tumor suppressor.
| Sprouty/Spred and breast cancer
The expression of Sprouty1 and Sprouty2 is reported to be downregulated in human breast cancer samples, and overexpression of the dominant negative form of human Sprouty2 in breast cancer cells promotes cell proliferation and anchorage-independent growth. 45 Another paper reported that the expression of Sprouty2 is inversely correlated with human epidermal growth factor receptor 2 (HER2) expression and is an independent prognostic marker in breast cancer. 46 However, it has also been reported that Sprouty1 knockdown in a human breast cancer cell line suppressed cell proliferation, migration, and colony formation. 75 Stromal Sprouty1 expression regulates mammary branching morphogenesis by modulating EGFR-dependent paracrine signaling and ECM remodeling. 76 This mechanism might be related to mammary tumorigenesis.
Sprouty4 also appears to function as a tumor suppressor in human breast cancer cells. 2 MicroRNA-196a is known to be involved in estrogen-induced breast cancer development and directly inhibits Spred1 and the tumorigenic activity of miR-196a is due to the suppression of Spred1. 
| Sprouty and gynecological cancer
In human endometrial carcinoma, Sprouty2 is silenced because of promoter hypermethylation. 2 In human high-grade serous ovarian carcinoma, the expression of Sprouty2, but not of Sprouty1 and Sprouty4, is decreased, and Sprouty2 loss enhances EGF-or amphiregulin-mediated E-cadherin downregulation and cell invasion. 77 The suppression of Sprouty1 promotes the proliferation and invasion of human ovarian cancer cell lines. 48 Moreover, low expression of Sprouty1 and Sprouty2, but not of Sprouty4, is associated with poor prognosis in patients with human epithelial ovarian cancer. 48, 49 Finally, decreased expression of Sprouty2 is associated with posttreatment development of ascites in carbotaxol-treated patients with epithelial ovarian cancer. 
| Sprouty and lung cancer
Sprouty2, but not Sprouty1, is downregulated in human NSCLC. 50 In a urethane-induced mouse lung tumor model, overexpression of Sprouty2 inhibited tumor initiation and growth. 2 Consistent with this report, Sprouty2 was shown to regulate lung tumorigenesis in a K-ras G12D -mediated lung tumor model. 2 In human NSCLC lines, Sprouty4 suppresses cell proliferation, invasion, and EMT. 2 Trametinib, an MEK inhibitor, suppresses Sprouty4 expression, leading to FGFR1-FRS2 activation, in mesenchymal-like K-rasmutant NSCLC. 79 Downregulation of Sprouty4 by an EGFR inhibitor also contributes to the emergence of tolerant lung cancer cells. 80 The role of Spreds in lung cancer has not yet been investigated.
| Sprouty and brain tumors
Sprouty2 expression is upregulated and is associated with poor prognosis in GBM patients. 81 Sprouty2 promotes ERK activation, proliferation, and drug resistance in GBM. 81, 82 Moreover, Sprouty1
is induced by insulin-like growth factor binding protein-2 through the nuclear factor-κB (NF-κB) pathway, which might play an important role in maintenance of the mesenchymal phenotypes of GBM cells. 
| Sprouty/Spred and hematological malignancies
In B-cell lymphoma, Sprouty2 is epigenetically silenced and promotes cell proliferation. 2 Sprouty2 is also downregulated in chronic lymphocytic leukemia and is an important negative regulator of B-cell receptor-mediated ERK activation. 52 In multiple myeloma, Sprouty2 is downregulated by miR-21 expression. 15, 86 High expression of Sprouty4 is associated with a favorable prognosis in patients with AML. Furthermore, the importance of Sprouty expression appears to be dependent on oncogenic Ras mutations in certain tumors. 2 In addition, the expression of the Sprouty/Spred family in CD8 + T cells might contribute to the suppression of antitumor immunity. 30, 31 Therefore, when the Sprouty/Spred family is targeted in cancer therapy, these should be taken into consideration to avoid unexpected results of the targeted therapy.
